Serelaxin

Summary

Serelaxin (CHEMBL2108358) is a phase-3 clinical-stage unknown (ATC C01DX21); indicated across 6 conditions including cardiovascular disorder and heart failure.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Unknown
• ATC class: C01DX21
• Indications: 6 conditions
• Clinical trials: 16

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL2108358
Name	Serelaxin
Type	Unknown
Max phase	3
ATC	C01DX21

Also known as: Human relaxin 2 (relaxin h2), Human relaxin recombinant, Recombinant human relaxin, RLX-030, RLX030, Serelaxin, Serelaxina, Serelaxine, SERELAXIN

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

6 diseases in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.

Disease (in trials)	Phase	MONDO	EFO
cardiovascular disorder	3	MONDO:0004995	EFO:0000319
heart failure	3	MONDO:0005252	EFO:0003144
preeclampsia	2	MONDO:0005081	EFO:0000668
coronary artery disorder	2	MONDO:0005010	EFO:0001645
liver disorder	1	MONDO:0005154	EFO:0001421
chronic kidney disease	1	MONDO:0005300	EFO:0003884

Clinical trials

Total trials: 16.

Phase distribution

Phase	Trials
PHASE2	11
PHASE3	3
PHASE1	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT01870778	PHASE3	COMPLETED	Efficacy, Safety and Tolerability of Serelaxin When Added to Standard Therapy in AHF
NCT02007720	PHASE3	TERMINATED	Efficacy, Safety and Tolerability of Sexelaxin When Added to Standard Therapy in AHF
NCT02064868	PHASE3	TERMINATED	Effect of Serelaxin Versus Standard of Care in Acute Heart Failure (AHF) Patients
NCT00259103	PHASE2	COMPLETED	Recombinant Human Relaxin (rhRlx) in Pregnant Women Scheduled for Induction of Labor
NCT01543854	PHASE2	COMPLETED	Hemodynamic Responses to RLX030 Infusion in Subjects With Acute Heart Failure
NCT01546532	PHASE2	COMPLETED	Renal Hemodynamic Effects of RLX030A in Subjects With Chronic Heart Failure (CHF)
NCT01566630	PHASE2	TERMINATED	Safety and Efficacy of RLX030 in Pregnant Women With Pre- Eclampsia
NCT01640964	PHASE2	COMPLETED	An Exploratory Haemodynamic Study in Patients With Compensated Cirrhosis and Portal Hypertension
NCT01979614	PHASE2	COMPLETED	Study of the Vascular Effects of Serelaxin
NCT01982292	PHASE2	COMPLETED	Safety of Repeat Doses of IV Serelaxin in Subjects With Chronic Heart Failure
NCT02002702	PHASE2	COMPLETED	Study of Safety, Tolerability and Pharmacokinetics of Serelaxin in Japanese Acute Heart Failure (AHF) Patients
NCT02151383	PHASE2	TERMINATED	Pharmacokinetics & Safety of Serelaxin on Top of Standard of Care Therapy in Pediatric Patients With Acute Heart Failure
NCT02625922	PHASE2	TERMINATED	Study of the Effect of Serelaxin on High-sensitivity Cardiac Troponin I (Hs-cTnI) Release in Patients With Chronic Heart Failure
NCT02669875	PHASE2	COMPLETED	Serelaxin To Lower Portal Pressure
NCT00333307	PHASE1	SUSPENDED	Evaluation of the Safety of Relaxin in Preeclampsia
NCT01875523	PHASE1	COMPLETED	PK of Serelaxin in Severe Renal Impairment and ESRD

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).